Product review: avelumab, an anti-PD-L1 antibody
Although immunotherapies have been employed for many decades, immune checkpoint inhibitors have only recently entered the oncologic landscape. Avelumab is a fully human monoclonal antibody that blocks the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby inhibiting immunosuppress...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2019-04-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2018.1551671 |
| _version_ | 1797677447784693760 |
|---|---|
| author | Julie M. Collins James L. Gulley |
| author_facet | Julie M. Collins James L. Gulley |
| author_sort | Julie M. Collins |
| collection | DOAJ |
| description | Although immunotherapies have been employed for many decades, immune checkpoint inhibitors have only recently entered the oncologic landscape. Avelumab is a fully human monoclonal antibody that blocks the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby inhibiting immunosuppression in the tumor microenvironment and reducing tumor growth. Most early clinical trials of avelumab as monotherapy and in combination regimens were part of the international JAVELIN clinical trial program, which included more than 7000 patients in more than 30 trials with at least 15 tumor types. Avelumab has been approved by the U.S. FDA for the treatment of metastatic Merkel cell carcinoma and metastatic urothelial carcinoma that has progressed during or following treatment with a platinum-based regimen. Its acceptable safety profile and ability to induce durable responses in otherwise deadly tumors provide the rationale for its use in other tumor types and in combination with other therapies. |
| first_indexed | 2024-03-11T22:45:19Z |
| format | Article |
| id | doaj.art-eef4569b67f14718adf5d38981dec890 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:45:19Z |
| publishDate | 2019-04-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-eef4569b67f14718adf5d38981dec8902023-09-22T08:38:24ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2019-04-0115489190810.1080/21645515.2018.15516711551671Product review: avelumab, an anti-PD-L1 antibodyJulie M. Collins0James L. Gulley1National Cancer Institute, National Institutes of HealthNational Cancer Institute, National Institutes of HealthAlthough immunotherapies have been employed for many decades, immune checkpoint inhibitors have only recently entered the oncologic landscape. Avelumab is a fully human monoclonal antibody that blocks the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby inhibiting immunosuppression in the tumor microenvironment and reducing tumor growth. Most early clinical trials of avelumab as monotherapy and in combination regimens were part of the international JAVELIN clinical trial program, which included more than 7000 patients in more than 30 trials with at least 15 tumor types. Avelumab has been approved by the U.S. FDA for the treatment of metastatic Merkel cell carcinoma and metastatic urothelial carcinoma that has progressed during or following treatment with a platinum-based regimen. Its acceptable safety profile and ability to induce durable responses in otherwise deadly tumors provide the rationale for its use in other tumor types and in combination with other therapies.http://dx.doi.org/10.1080/21645515.2018.1551671avelumabmonoclonal antibodyanti-pd-l1immune checkpoint inhibitorimmunotherapymsb0010718cmerkel cell carcinomaurothelial carcinoma |
| spellingShingle | Julie M. Collins James L. Gulley Product review: avelumab, an anti-PD-L1 antibody Human Vaccines & Immunotherapeutics avelumab monoclonal antibody anti-pd-l1 immune checkpoint inhibitor immunotherapy msb0010718c merkel cell carcinoma urothelial carcinoma |
| title | Product review: avelumab, an anti-PD-L1 antibody |
| title_full | Product review: avelumab, an anti-PD-L1 antibody |
| title_fullStr | Product review: avelumab, an anti-PD-L1 antibody |
| title_full_unstemmed | Product review: avelumab, an anti-PD-L1 antibody |
| title_short | Product review: avelumab, an anti-PD-L1 antibody |
| title_sort | product review avelumab an anti pd l1 antibody |
| topic | avelumab monoclonal antibody anti-pd-l1 immune checkpoint inhibitor immunotherapy msb0010718c merkel cell carcinoma urothelial carcinoma |
| url | http://dx.doi.org/10.1080/21645515.2018.1551671 |
| work_keys_str_mv | AT juliemcollins productreviewavelumabanantipdl1antibody AT jameslgulley productreviewavelumabanantipdl1antibody |